Tocilizumab da Sarilumab An Sami Tasiri a Kula da Majinyatan COVID-19 masu Muhimmanci

Rahoton farko na sakamakon da aka samu daga gwajin asibiti na NCT02735707 da aka ruwaito a cikin bugu na farko ya nuna cewa Tocilizumab da Sarilumab, magungunan hana karɓar interleukin-6 suna da tasiri wajen kula da marasa lafiya da ke fama da COVID-19 masu tsanani da kuma inganta rayuwa.

Marasa lafiya masu fama da cutar COVID-19 masu tsananin rashin lafiya waɗanda suka sami tallafin kulawa mai zurfi sun amsa da kyau ga maganin da aka yi musu da magungunan agonists na IL-6, tocilizumab da sarilumab. Mutuwar asibiti ta kasance kashi 28.0% ga tocilizumab, kashi 22.2% ga sarilumab da kashi 35.8% don kulawa, ma'ana ƙimar rayuwa ta inganta tare da tallafawa ingantaccen ingancin waɗannan magungunan da aka sake amfani da su. ⁽¹⁾

Ana amfani da magungunan tocilizumab (wani maganin rigakafi na monoclonal da aka yi wa ɗan adam akan mai karɓar IL-6) da kuma sarilumab (wani maganin rigakafi na monoclonal na ɗan adam akan mai karɓar IL-6) a matsayin magungunan rage ƙarfin garkuwar jiki wajen magance cututtukan arthritis.

A cikin yanayin da ake ciki a yanzu na annobar COVID-19, lokacin da mace-mace da kamuwa da cuta ke da yawa, abin sha'awa ne a lura cewa waɗannan magungunan biyu da aka sake amfani da su sun rage yawan zaman marasa lafiya na COVID-19 a cikin ɗakunan kulawa na gaggawa na asibiti sosai, kuma sun rage yawan mace-mace da kusan kwata. Wannan yana nufin ƙarancin mace-mace da kuma ɗan gajeren zama a cikin kulawa mai mahimmanci, don haka yana kiyaye ƙarfin asibitoci don magance annobar.

Wannan gwajin asibiti an ba shi kuɗi ne daga ƙungiyar EU wadda ke tallafawa REMAP-CAP ta hanyar shirin shirye-shiryen Turai kan (Sake) barkewar annoba (PREPARE). Ƙarin tallafi ya fito ne daga aikin Rapid European SARS-CoV-2 Response Response (RECOVER) ⁽²⁾.

***

Sources:  

1. Masu bincike na REMAP-CAP, Gordon AC., 2020. Interleukin-6 Masu adawa da Mai karɓa a cikin Marasa lafiya marasa lafiya tare da Covid-19 - Rahoton farko. Preprint: MedRxiv. An buga Janairu 07, 2021. DOI: https://doi.org/10.1101/2021.01.07.21249390  

2. Hukumar Tarayyar Turai, 2021. Labarai - Gwajin gwaji na asibiti na EU ya gano sabbin jiyya don yin tasiri a kan COVID-19. An buga 8 Janairu 2021. Akwai akan layi https://ec.europa.eu/info/news/eu-funded-clinical-trial-finds-new-treatments-be-effective-against-covid-19-2021-jan-08_en&pk_campaign=rtd_news 

3.  Gwajin Clinical NCT02735707: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP) Akwai akan layi a  https://clinicaltrials.gov/ct2/show/NCT02735707?term=NCT02735707&cond=Covid19&draw=2&rank=1#contacts 

***